Beneficial Effects of Cannabis on Blood Brain Barrier Function in HIV
Clinical infectious diseases, 2020 Apr 16, ciaa437.
Doi : 10.1093/cid/ciaa437
Background: HIV infection leads to blood-brain barrier (BBB) dysfunction that does not resolve despite viral suppression on antiretroviral therapy and is associated with adverse clinical outcomes. In preclinical models, cannabis restores BBB integrity.
Methods: We studied people with HIV (PWH) and HIV- individuals who had used cannabis recently. We assessed two biomarkers of BBB permeability: the cerebrospinal fluid [CSF]-to-serum albumin ratio [CSAR], and CSF levels of soluble urokinase plasminogen activator receptor [suPAR], a receptor for uPA, a matrix-degrading proteolytic enzyme that disrupts the BBB. A composite index of the BBB markers was created using principal components analysis. Neural injury was assessed using neurofilament light (NFL) in CSF by immunoassay.
Results: Participants were 45 PWH and 30 HIV- individuals of similar age and ethnicity. Among PWH, higher CSF suPAR levels correlated with higher CSAR values (r=0.47; p<0.001). PWH had higher (more abnormal) BBB index values than HIV- individuals (mean +/- SD 0.361 +/-1.20 versus -0.501 +/- 1.11; p=0.0214). HIV serostatus interacted with cannabis use frequency such that more frequent use of cannabis was associated with lower BBB index values in PWH but not in HIV-. Worse BBB Index values was associated with higher NFL in CSF (r=0.380, p=0.0169).
Conclusions: Cannabis may have a beneficial impact on HIV-associated BBB injury. Since BBB disruption may permit increased entry of toxins such as microbial antigens and inflammatory mediators, with consequent CNS injury, these results support a potential therapeutic role of cannabis among PWH and may have important treatment implications for ART effectiveness and toxicity.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: email@example.com.
Neurol Neuroimmunol Neuroinflamm, 2016 Nov 9, 3, (6), e300.doi : 10.1212/NXI.0000000000000300.eCollection 2016 Dec. Free PMC article.
J Neuroimmunol, 2002 Aug, 129, (1-2), 216-223.doi : 10.1016/s0165-5728(02)00186-8.
EBioMedicine, 2015 Nov 22, 3, 135-140.doi : 10.1016/j.ebiom.2015.11.036.eCollection 2016 Jan. Free PMC article.
Frontiers in Bioscience, 2004 Sep 1, 9, 2680-5.doi : 10.2741/1427. Review.
Curr Drug Metab, 2015, 16, (2), 105-23.doi : 10.2174/138920021602150713114715. Review.